+ Spearheading a global coalition of clinicians and researchers to publish and adopt the first biological , rather than clinical , staging system for Parkinson ’ s .
+ Leveraging the biomarker and the infrastructure of our PPMI study to launch the first-ever prevention trials in Parkinson ’ s , expected to commence in 2025 .
+ Partnering with academic , biotech and pharmaceutical teams to integrate the new biological tools into near-term and ongoing clinical trials to accelerate the path toward precision medicine , that is , therapies tailored to an individual ’ s specific biological profile .
This is a time of unprecedented momentum and opportunity in Parkinson ’ s drug development . With new tools and expanded investments we are within reach of our ultimate goal of eradicating the disease altogether .
We ' re here to do what we have promised to do : provide the strategic leadership and commensurate funding to achieve our vision of transformational advances in treating and preventing Parkinson ’ s disease . It ' s bold , ambitious , risky , yes . But it ' s also in our reach .
We ’ re awed and inspired by you — the millions of people around the world who support us in our work and who have unleashed unprecedented research momentum and positive outcomes on a greater scale than ever before . We need and depend on your partnership to sustain and grow this momentum . Together we will continue to transform and accelerate the course of Parkinson ’ s research for the benefit of every patient and family living with this disease .
Debi Brooks CEO and Co-Founder
2